Month: February 2024

ATHENS, Greece, Feb. 16, 2024 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that it will release its financial results for the fourth quarter ended December 31, 2023, on February 21, 2024 before market opens in New York. On the same day, Wednesday, February 21, 2024 at 9:00 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results. Conference Call details:Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote “Euroseas” to the operator and/or conference ID 13744700.Click here for additional...

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today at 4:15 p.m. ET, February 16, 2024. To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e. To listen to the live or archived webcast, please register at https://edge.media-server.com/mmc/p/uqbbcfz4/. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year. About Iovance...

AMTAGVI (lifileucel) Product ShotAMTAGVI (lifileucel) product packagingAMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved AMTAGVI™ (lifileucel) suspension for intravenous infusion. AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with...

NOT FOR DISTRIBUTION TO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Vancouver, British Columbia, Feb. 16, 2024 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce closing of a second and final tranche of a non-brokered private placement financing (see previous News Releases dated December 20, 2023 and January 5, 2024) of 2,656,250 common shares of the Company (the “Common Shares”) issued at a price of C$0.32 per Common Share for gross proceeds of C$850k (the “Offering”). The Company increased the total size of the Private Placement to $2.35 million gross proceeds due to investor interest. A total of 7,343,750 Common Shares were issued under the first and second tranches for $2.35 million gross proceeds. NevGold CEO, Brandon Bonifacio, comments: “It...

Banco Comercial Português, S.A. informs on a notice received from Bank of America CorporationAttachment2024 02 16 Participação qualificada EN

Sharps and Roncadelle are Joining Forces to Supply Drug Delivery Systems to the International HealthCare Market Through an Expanded Network of North American 3PL Distribution Partnerships NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) — Sharps Technology, Inc., (NASDAQ: STSS) (NASDAQ: STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies...

PRESS RELEASE ISSUANCE OF A 9.6-YEAR BOND FOR €600M Paris, February 16, 2024 Klépierre, the European leader in shopping malls, today announces the issuance of a €600-million bond with a maturity of 9.6 years. This financing has been raised with a 130 basis points spread over the reference rate, for a coupon of 3.875%. This issuance has been oversubscribed more than 5 times.INVESTOR RELATIONS CONTACTS MEDIA CONTACTSPaul Logerot, Group Head of IR and Financial Communication +33 (0)7 50 66 05 63 — paul.logerot@klepierre.comHugo Martins, IR Manager +33 (0)7 72 11 63 24 — hugo.martins@klepierre.com  Tanguy Phelippeau, IR Manager +33 (0)7 72 09 29 57 — tanguy.phelippeau@klepierre.com Hélène Salmon, Group Head of Communication +33 (0)1 40 67 55 16 — helene.salmon@klepierre.com   Wandrille Clermontel, Taddeo +33 (0)6 33 05 48 50 — teamklepierre@taddeo.frABOUT...